Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 15Melanotan II literaturePubMed · Case report2026

Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.

Melanotan II injections can lead to noticeable pigmentation changes in the oral mucosa, which may persist even after stopping the injections.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the melanotan ii corpus
5
Preclinical
9
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This case report examines the effects of Melanotan II injections on oral mucosa over a three-month period in a patient who self-administered the peptide for tanning. Observations included brown pigmentation on the gingiva and buccal mucosa, with changes noted at one and three months post-injection. The findings contribute to the limited literature on the oral effects of Melanotan II.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as PubMed supplied them

This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect. Melanotan II is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family. It acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and resulting in skin pigmentation independent of sun exposure. Despite its popularity, particularly through promotion on social media, Melanotan II remains unregulated, and its use is associated with a range of potential adverse effects. During the initial intraoral examination, brown pigmentation was observed on the attached gingiva in both the maxillary and mandibular arches. The lesions were almost symmetrically distributed, with a more intense coloration in the anterior region of the lower jaw. Additional pigmented areas with irregular shapes and poorly defined borders were noted on the left and right buccal mucosa. At the one-month follow-up after discontinuation of the injections, the buccal mucosal pigmentation had nearly disappeared. However, at the three-month follow-up, gingival pigmentation persisted, though with visibly reduced intensity. To date, there is a lack of published data specifically addressing the timeline for resolution of oral pigmentation associated with Melanotan II use, making this case a valuable contribution to the limited existing literature on the subject.

Background

This paper addresses the effects of Melanotan II on oral mucosa, a topic that has not been extensively studied in the literature. Prior research has primarily focused on the systemic effects of Melanotan II, particularly in relation to skin pigmentation. Understanding local effects, such as those on oral tissues, is important for a comprehensive evaluation of the peptide's safety profile.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Melanotan II corpus

DControlling mountain-type zoonotic visceral leishmaniasis in China: Current progress and challenges through a One Health lens.One health (Amsterdam, Netherlands) · 2026 · Average total score was 47.77/100 (range: 38.59-61.72).reviewDDirect photoreception by pituitary endocrine cells regulates hormone release and pigmentation.Science (New York, N.Y.) · 2025DLeptin enhances the intracellular thyroid hormone activation in skeletal muscle to boost energy balance.Cell metabolism · 2025ATebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.Human vaccines & immunotherapeutics · 2026 · Not reported in abstract.reviewBIntegrative multi-omics Mendelian randomization reveals key lipid metabolism genes as therapeutic targets for diabetic nephropathy pathogenesis.Renal failure · 2026 · n=100000 · CERS2: OR = 1.246, p_SMR = 0.027reviewBAssessing nutritional risk and its association with mortality in ICU patients using the modified NUTRIC score: evidence from a tertiary care hospital.Annals of medicine · 2026 · n=584 · Adjusted odds ratio for low nutritional risk associated with mortality was 0.51 (95% CI 0.28-0.91).Human